On December 1, 2022, Theratechnologies announced the decision to voluntarily pause the enrollment of patients in its Phase 1 clinical trial of TH1902, the Company’s lead investigational peptide drug conjugate for the treatment of sortilin-expressing cancers. Following the voluntary pause, the Company formed a Scientific Advisory Committee to help determine the best developmental path forward for TH1902. A meeting was held on March 22, with several medical oncologists from across the United States, who are leading experts in the end-to-end lifecycle of oncology drug development. Theratechnologies presented the pre-clinical and clinical data gathered thus far to the SAC, which made recommendations to modify the frequency of administration, selection of tumor types and refined criteria for patient selection to further improve our chances of a successful outcome. The Company is finalizing adjustments to the protocol and aims to submit to the FDA before the end of April 2023. Consistent with the Company’s 2023 objective of generating positive Adjusted EBITDA by fiscal year end, any new investments in TH1902 will be stage-gated. Once the Phase 1 clinical trial has resumed, Theratechnologies will also evaluate potential partnerships for TH1902.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on THTX:
- Theratechnologies Reports Financial Results and Business Updates for First Quarter 2023
- Theratechnologies to Announce First Quarter 2023 Financial Results and Provide Business Update
- Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model
- Theratechnologies receives Nasdaq non-compliance notification letter
- Theratechnologies Receives Nasdaq Notification Letter Regarding Share Price